Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.73 |
| ▸ | LOX | P28300 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12802921 | 0.98 | LOXL2 (0.71) | LOXL2LOXKDM4EATMTAAR1 | |
| Hydrochloric Acid SCHEMBL2022971 | 0.98 | LOXL2 (0.71) | LOXL2LOXKDM4EATMTAAR1 | |
| SCHEMBL21591576 | 0.89 | LOXL2 (0.69) | LOXL2LOXKDM4EATMTAAR1 | |
| SCHEMBL22336235 | 0.85 | LOXL2 (0.68) | LOXL2LOXKDM4EATMFFAR1 | |
| SCHEMBL449200 | 0.85 | LOXL2 (1.00) | LOXL2LOX | |
| Hydrochloric Acid SCHEMBL463199 | 0.83 | LOXL2 (0.96) | LOXL2LOXMAOB | |
| SCHEMBL12093687 | 0.83 | LOXL2 (0.65) | LOXL2LOXKDM4ETSHRLMNA | |
| SCHEMBL2497237 | 0.81 | LOXL2 (0.62) | LOXL2LOXKDM4EFFAR1 | |
| SCHEMBL14486857 | 0.81 | LOXL2 (0.62) | LOXL2LOXFFAR1 | |
| SCHEMBL12093676 | 0.81 | LOXL2 (0.62) | LOXL2LOXFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| CN-105164118-A | Antibacterial phthalide derivatives | ACTELION PHARMACEUTICALS LTD | 2015-12-16 | — | — | CN | disclosed |
| EP-2435019-B1 | DODECA-2E,4E-DIENE AMIDES AND THEIR USE AS MEDICAMENTS AND COSMETICS | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8921383-B2 | Thiazolopyrimidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921383-B2 | Thiazolopyrimidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2010136221-A1 | DODECA-2E,4E-DIENE AMIDES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2010-12-02 | — | — | WO | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | SYK, BTK, ZAP70 | LOXL2 2997/4885LOX 2322/4885KDM4E 1023/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | LOXL2 4518/4885LOX 4854/4885KDM4E 4646/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | LOXL2 2975/4885LOX 3775/4885KDM4E 3952/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | LOXL2 2975/4885LOX 3775/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.